📊 SMTI Key Takeaways
Is Sanara MedTech Inc. (SMTI) a Good Investment?
Strong revenue growth (19% YoY) and exceptional gross margins (93.1%) are overshadowed by severe financial stress: negative operating cash flow (-$2.5M) despite positive net income signals poor earnings quality, while extreme leverage (6.58x debt/equity) with weak interest coverage (1.5x) creates acute default risk. The company's 1.7% net margin provides insufficient buffer to service $46.2M debt against only $7.0M equity.
Sanara MedTech Inc. Key Strengths (SMTI)
- Revenue growth of 19% YoY demonstrates market demand
- Gross margin of 93.1% indicates strong pricing power and product quality
- Current ratio of 2.28x and $13.6M cash provides near-term liquidity buffer
SMTI Stock Risks: Sanara MedTech Inc. Investment Risks
- Negative operating cash flow (-$2.5M) despite positive net income indicates severe earnings quality deterioration and poor cash conversion
- Extreme leverage with 6.58x debt/equity ratio and only 1.5x interest coverage creates imminent default risk if operations deteriorate further
- Divergence between accounting profitability and cash generation is unsustainable; at -$2.5M annual burn, cash reserves deplete in 5-6 years
Key Metrics to Watch
- Operating cash flow trend - must turn positive to validate sustainability
- Interest coverage ratio - currently critical; needs improvement above 2.5x
- Debt reduction progress and refinancing timeline - leverage must decline to healthy levels
Sanara MedTech Inc. (SMTI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.28x current ratio provides a solid financial cushion.
SMTI Profit Margin, ROE & Profitability Analysis
SMTI vs Healthcare Sector: How Sanara MedTech Inc. Compares
How Sanara MedTech Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sanara MedTech Inc. Stock Overvalued? SMTI Valuation Analysis 2026
Based on fundamental analysis, Sanara MedTech Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sanara MedTech Inc. Balance Sheet: SMTI Debt, Cash & Liquidity
SMTI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sanara MedTech Inc.'s revenue has grown significantly by 327% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.14 indicates the company is currently unprofitable.
SMTI Revenue Growth, EPS Growth & YoY Performance
SMTI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $23.4M | $459.0K | $0.05 |
| Q3 2025 | $21.7M | -$2.9M | $-0.34 |
| Q2 2025 | $20.2M | -$2.0M | $-0.23 |
| Q1 2025 | $18.5M | -$1.8M | $-0.21 |
| Q3 2024 | $16.0M | -$1.1M | $-0.13 |
| Q2 2024 | $15.8M | -$1.8M | $-0.22 |
| Q1 2024 | $15.5M | -$1.2M | $-0.14 |
| Q3 2023 | $13.0M | -$1.1M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sanara MedTech Inc. Dividends, Buybacks & Capital Allocation
SMTI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sanara MedTech Inc. (CIK: 0000714256)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SMTI
What is the AI rating for SMTI?
Sanara MedTech Inc. (SMTI) has an AI grade of D with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SMTI's key strengths?
Claude: Revenue growth of 19% YoY demonstrates market demand. Gross margin of 93.1% indicates strong pricing power and product quality.
What are the risks of investing in SMTI?
Claude: Negative operating cash flow (-$2.5M) despite positive net income indicates severe earnings quality deterioration and poor cash conversion. Extreme leverage with 6.58x debt/equity ratio and only 1.5x interest coverage creates imminent default risk if operations deteriorate further.
What is SMTI's revenue and growth?
Sanara MedTech Inc. reported revenue of $27.8M.
Does SMTI pay dividends?
Sanara MedTech Inc. pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find SMTI SEC filings?
Official SEC filings for Sanara MedTech Inc. (CIK: 0000714256) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SMTI's EPS?
Sanara MedTech Inc. has a diluted EPS of $0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SMTI's fundamental grade?
Based on our AI fundamental analysis in May 2026, Sanara MedTech Inc. has a D grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SMTI stock overvalued or undervalued?
Valuation metrics for SMTI: ROE of 6.5% (sector avg: 15%), net margin of 1.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SMTI's AI grade for 2026?
Our dual AI analysis gives Sanara MedTech Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SMTI's free cash flow?
Sanara MedTech Inc.'s operating cash flow is $-2.5M, with capital expenditures of $43.8K. FCF margin is -9.0%.
How does SMTI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.7% (avg: 12%), ROE 6.5% (avg: 15%), current ratio 2.28 (avg: 2).
Is Sanara MedTech Inc. carrying too much debt?
SMTI has a debt-to-equity ratio of 6.58x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.28 suggests adequate short-term liquidity.